冠心病患者氯吡格雷低反应性药物基因组学及药物效应动力学的研究
|
摘要
研究背景
氯吡格雷抑制血小板聚集具有个体差异性。研究发现部分患者使用氯吡格雷后仍有死亡、心肌梗死、中风或支架内血栓形成等严重不良缺血心血管事件发生,该现象称之为氯吡格雷低反应性。遗传因素是氯吡格雷低反应性的发生机制之一。目前尚不明确国人冠心病患者氯吡格雷代谢通路上相关基因的功能多态性位点与服用氯吡格雷后的血小板功能及不良临床预后的相关性。
研究目的
本研究拟验证国人冠心病患者氯吡格雷代谢通路上相关基因(ABCB1、CYP2C19、CYP3A、CYP3A5和口P2Y12)的功能多态性位点与服用氯吡格雷后的血小板功能及不良临床预后的相关性。
对象和方法
2012年1月到2013年2月入选收住我院拟行经皮冠状动脉介入治疗并置入支架的冠心病患者1408例。多重高温连接酶检测反应技术检测ABCB1、CYP2C19、 CYP3A4、CYP3A5和P2Y12基因上的15个功能多态性位点。血栓弹力图检测支架置入术后服用氯吡格雷24小时以内的血小板功能。所有入选患者均正规服用氯吡格雷12个月,并进行为期一年的临床随访。主要终点事件是指严重不良心血管事件,包括死亡、非致死性心肌梗死、靶血管血运重建或支架内血栓形成等复合终点事件；次要终点事件是指支架置入术后一年随访期间的死亡、非致死性心肌梗死、靶血管血运重建和支架内血栓形成。
研究结果
本研究入选国人冠心病患者携带CYP2C19功能缺失等位基因(*2和*3)的频率高达59.3%。携带两个CYP2C19功能缺失等位基因的患者与携带一个CYP2C19功能缺失等位基因或未携带CYP2C19功能缺失等位基因的患者相比,服用氯吡格雷后的血小板抑制率最低(44.6±31.1vs.52.0±30.0vs.55.4±30.5;P=0.001)。62位(4.4%)患者支架置入术后一年随访期间发生严重不良心血管事件。携带两个CYP2C19功能缺失等位基因的患者与携带一个CYP2C19功能缺失等位基因或未携带CYP2C19功能缺失等位基因的患者相比,严重不良心血管事件的发生率最高(7.5%vs.4.9%vs.2.8%；P=0.016)。多变量Cox回归分析发现：携带两个CYP2C19功能缺失等位基因的患者与未携带CYP2C19功能缺失等位基因的患者相比,支架置入术后一年随访期间严重不良心血管事件的发生率升高近3倍(HR=2.962；95%CI：1.426-6.152；P=0.004)：携带一个CYP2C19功能缺失等位基因的患者与未携带CYP2C19功能缺失等位基因的患者相比,严重不良缺血心血管事件的发生率没有明显升高(HR=1.833；95%CI：0.986-3.406；P=0.055)。氯吡格雷代谢通路上其他基因(ABCB1、CYP3A4、CYP3A5、和P2Y12)的功能多态性位点与国人冠心病患者服用氯吡格雷后的血小板反应性和支架置入术后一年随访期间严重不良心血管事件无明显相关性(P>0.05)。结论
携带两个CYP2C19功能缺失等位基因的国人冠心病患者与服用氯吡格雷后的血小板功能和支架置入术后一年随访期间的严重不良心血管事件有明确相关性；携带两个CYP2C19功能缺失等位基因是国人冠心病患者支架置入术后一年随访期间严重不良心血管事件的独立预测因素；氯吡格雷代谢通路上其他基因(ABCB1、CYP3A4、CYP3A5和P2Y12)的功能多态性位点与国人冠心病患者服用氯吡格雷后的血小板功能和支架置入术后一年随访期间严重不良心血管事件无显著相关性。
研究背景
研究证实服用抗血小板药物后的残存血小板高反应性可能与不良的临床预后有相关性。血小板功能检测方法是评价冠心病患者体内血小板活性和服用抗血小板药物后残存血小板反应性的实验室检测手段。目前血小板功能检测方法众多,例如光学比浊法,血栓弹力图,VerifyNow快速分析仪,活化舒血管磷蛋白磷酸化的检测等。哪种检测方法能更为准确特异的反应血小板功能和预测临床预后结果尚无明确结论,尤其是中国冠心病患者服用氯吡格雷后的血小板高反应性更无统一的诊断标准。
研究目的
本研究拟比较光学比浊法和血栓弹力图两种方法检测服用氯吡格雷后血小板高反应性的相关性及探讨对国人冠心病患者支架置入术后不良临床预后的预测价值。
对象和方法
2012年1月到2013年2月入选收住我院已行经皮冠状动脉介入治疗并置入支架的冠心病患者789例。服用氯吡格雷24小时以内,所有患者均采用光学比浊法和血栓弹力图两种方法检测血小板功能。所有入选患者支架置入术后均进行为期一年的临床随访。严重不良心血管事件是指支架置入术后一年随访期间死亡、非致死性心肌梗死、靶血管血运重建或支架内血栓形成等复合终点事件。
研究结果
支架置入术后一年随访期间,有32例患者(4.1%)发生严重不良心血管事件,其中有5例发生非致死性心肌梗死,3例患者发生支架内血栓,26例患者行靶血管血运重建。光学比浊法和血栓弹力图两种方法检测服用氯吡格雷后的残余血小板反应有相关性(Spearman r=0.733,P<0.001)。ROC曲线分析表明,支架置入术后一年的随访期间,光学比浊法(曲线下面积：0.677；95%可信区间：0.643-0.710；P=0.0009)和血栓弹力图(曲线下面积：0.684；95%可信区间：0.650-0.716；P=0.0001)两种检测方法均能一定程度的预测中国冠心病患者支架置入术后的严重不良心血管事件。光学比浊法评估服用氯吡格雷后血小板高反应性的患者严重不良心血管事件的发生率较血小板正常反应的患者明显升高(7.4%vs.2.7%；P=0.003)；血栓弹力图评估服用氯吡格雷后血小板高反应性的患者严重不良心血管事件的发生率较血小板正常反应的患者亦明显升高(6.7%vs.2.6%；P=0.005)。Kaplan-Meier分析表明,光学比浊法或血栓弹力图诊断为服用氯吡格雷后血小板高反应性的患者与血小板正常反应的患者相比,支架置入术后一年随访期间严重不良心血管事件的发生率明显升高(HR：2.752,95%CI：1.360-5.569,P=0.002；或HR：2.601；95%CI：1.279-5.290,P=0.005)
结论
光学比浊法和血栓弹力图两种血小板功能检测方法检测国人冠心病患者支架置入术后服用氯吡格雷的血小板功能,相关性较好；两种血小板功能检测方法均能一定程度上预测支架置入术后服用氯吡格雷的血小板高反应性患者发生严重不良心血管事件的风险明显升高。
研究背景
支架置入术后服用氯吡格雷的冠心病患者,是否应该常规检测CYP2C19基因分型和血小板功能以评估其临床预后尚不明确。本研究假设：整合CYP2C19基因分型和血小板功能检测两项结果是支架置入术后再发不良缺血心血管事件强有力的预测因素。
研究目的
本研究拟探讨CYP2C19基因分型联合血小板功能检测的两项结果预测国人冠心病患者支架置入术后一年随访期间的严重不良心血管事件。
对象和方法
2012年1月到2013年2月入选收住我院拟行经皮冠状动脉介入治疗并置入支架的冠心病患者1104例。多重高温连接酶检测反应技术进行CYP2C19基因分型(rs4244285和rs4986893)。服用氯吡格雷24小时以内,血栓弹力图检测入选患者的血小板功能。服用氯吡格雷后血小板高反应性定义为血栓弹力图检测二磷酸腺苷诱导的血小板抑制率≤30%。所有入选患者均正规服用氯吡格雷一年,并进行为期一年的临床随访。严重不良心血管事件包括死亡,非致死性心肌梗死,靶血管血运重建或支架内血栓形成等复合终点事件。
研究结果
47例(4.3%)患者支架置入术后一年随访期间发生严重不良心血管事件。多变量Cox回归模型分析CYP2C19基因分型的结果显示：CYP2C19功能缺失等位基因携带者(*1/*2、*1/*3、*2/*2、*2/*3和*3/*3)与未携带CYP2C19功能缺失等位基因的患者相比,支架置入术后一年随访期间严重不良心血管事件的发生风险升高近2.2倍(HR：2.195,95%CI：1.035-4.658,P=0.04)。多变量Cox回归模型分析服用氯吡格雷后的血小板功能,结果表明：服用氯吡格雷后血小板高反应性的患者与血小板正常反应的患者相比,支架置入术后一年随访期间严重不良心血管事件的发生风险也升高2.2倍左右(HR：2.218,95%CI：1.131-4.351,P=0.02)。通过多变量Cox回归模型分析CYP2C19基因分型联合血小板功能检测两项结果显示：携带CYP2C19功能缺失等位基因且服用氯吡格雷后血小板仍呈高反应性的患者,即2个阳性结果与无阳性结果(未携带CYP2C19功能缺失等位基因且服用氯吡格雷后血小板正常反应)的患者相比,PCI术后一年随访期间严重不良心血管事件(死亡非致死性心肌梗死、靶血管血运重建或支架内血栓形成等复合终点事件)的发生率升高近3.8倍(HR：3.777,95%CI：1.508-9.461,P=0.005)。CYP2C19基因分型联合血小板功能检测两项结果加入常规临床预测模型后,ROC曲线评估国人冠心病患者支架置入术后一年随访期间严重不良心血管事件的预测能力有所升高(AUC,from0.67to0.73；P=0.074),全部患者的净重新分类指数高达27.7%(P=0.003)整体鉴别指数是0.016(P=0.013)
结论
CYP2C19基因分型联合血小板功能检测均呈阳性结果的国人冠心病患者,支架置入术后一年随访期间严重不良心血管事件的发生率最高；CYP2C19基因分型联合血小板功能检测均呈阳性结果者,较单一CYP2C19基因分型或血小板功能检测,能更有效的预测国人冠心病患者PCI术后一年随访期间的严重不良心血管事件。
Background
Several studies have demonstrated wide inter-individual variability in the pharmacodynamic response to clopidogrel. Observational studies have linked a poor pharmacodynamic response to cardiovascular events after percutaneous coronary intervention (PCI), including death, recurrent myocardial infarction, stroke, or stent thrombosis. Genetic factors were considered as one of the mechanisms for clopidogrel hyporesposiveness. Effect of the ABCB1, CYP2C19, CYP3A4, CYP3A5, and P2Y12variants on platelet reactivity and clinical outcomes of clopidogrel has not been reported in Chinese patients undergoing PCI.
Objectives
The aim of this study was to investigate the effect of the ABCB1, CYP3A4, CYP3A5, and P2Y12variants on clopidogrel pharmacodynamics and clinical outcomes in these patients.
Methods
1408patients undergoing stent implantation were enrolled in a single-center registry. The ABCB1, CYP2C19, CYP3A4, CYP3A5, and P2Y12genotypes were detected by the improved multiple ligase detection reaction, and the antiplatelet effect of clopidogrel were assessed by thrombelastography. Primary clinical endpoint was defined as major adverse cardiovascular events (MACE), which included the composite of all-cause death, nonfatal myocardial infarction, target vessel revascularization, or stent thrombosis. The secondary clinical endpoints were all-cause death, nonfatal myocardial infarction, target vessel revascularization, and stent thrombosis during12-month follow-up.
Results
The carriage of the CYP2C19loss-of-function alleles was relatively high (59.3%).62(4.4%) patients had MACE during12-month follow-up. The lowest risk of response to clopidogrel (55.4±30.5vs.52.0±30.0vs.44.6±31.1; P=0.001) and the highest incidence of MACE (2.8%vs.4.9%vs.7.5%; P=0.016) increased with the number of CYP2C19loss-of-function alleles. In the multivariate Cox regression analysis, two CYP2C19LOF alleles (HR=2.962,95%CI:1.426-6.152, P=0.004) were associated with MACE compared with noncarriers; the carriers of one CYP2C19LOF allele (HR=1.833;95%CI:0.986-3.406; P=0.055) were not associated with MACE compared with noncarriers. However, there were no significant differences in clopidogrel pharmacodynamics and adverse ischemic events across the ABCB1, CYP3A4, CYP3A5and P2Y12genotype groups (P>0.05).
Conclusions
The CYP2C19loss-of-function alleles had a gene dose effect on the clopidogrel pharmacodynamics and major adverse cardiovascular events in our population. The carrage of two CYP2C19LOF alleles was an independent predictor of major adverse cardiovascular events in patients undergoing PCI during follow-up period. The antiplatelet effect and adverse clinical outcomes of clopidogrel were not significantly influenced by ABCB1, CYP3A4, CYP3A5and P2Y12genotype in these patients.
Background
Patients exhibiting heightened platelet reactivity to adenosine diphosphate (ADP) might be at increased risk for recurrent ischemic events after coronary stenting. Several platelet function tests are currently used to measure responsiveness to antiplatelet therapy.However, which test can be best to detect platelet function specifically and predict clincial outcomes was still uncertain. High on-treatment platelet reactivity of Chinese patients is still no uniform diagnostic criteria.
Objectives
The aim of our study was to whether patients receiving clopidogrel undergoing stenting who display high on-treatment platelet reactivity measured by light transmittance aggregometry (LTA) and thrombelastography (TEG) will be at increased risk for poststenting ischemic events.
Methods
Prospective, observational, single-center study of789Chinese patients underwent stent implantation. This study was investigated the correlations between the2tests (LTA and TEG) and performed receiver operating characteristic curve (ROC) analysis for major adverse cardiovascular events (MACE), a composite of death, myocardial infarction (MI), stent thrombosis, or target vessel revascularization, at1-year follow-up.
Results
Major adverse cardiovascular events occurred in32patients (4.1%), including5patients with recurrent MI,3patients with stent thrombosis, and26patients with target vessel revascularization. Correlations were strong between the2tests in the adenosine diphosphate induced platelet reactivity (Spearman r=0.733, P<0.001). ROC-curve analysis demonstrated that LTA (area under the curve [AUC],0.677;95%confidence interval [CI],0.643-0.710; P=0.0009), and TEG assay (AUC,0.684;95%CI,0.650-0.716; P=0.0001) had moderate ability to discriminate between patients with and without MACE at1-year follow-up. MACE occurred more frequently in patients with high on-treatment platelet reactivity (HTPR) when assessed by LTA (7.4%vs.2.7%; P=0.003), and by TEG (6.7%vs.2.6%; P=0.005). Kaplan-Meier analysis demonstrated that HTPR based on the LTA and modified TEG was associated with almost4-fold increased risk of MACE at1-year follow-up (HR:2.752,95%CI:1.360-5.569, P=0.005; HR:2.601;95%CI:1.279-5.290, P=0.008; respectively).
Conclusions The ADP-induced platelet aggregation by LTA and TEG showed a strong correlation. Hypo-responsiveness to clopidogrel measured by light transmittance aggregometry, and modified thrombelastography were significantly associated with MACE in Chinese patients undergoing stenting. However, the predictive accuracy of these two tests was moderate.
Background
Routine assessment of CYP2C19genotyping or platelet function after clopidogrel, which can be used to risk-stratify patients with coronary artery disease receiving stenting implantation, is still debated. We hypothesized that an aggregate risk evaluated by CYP2C19genotyping combined with platelet reactivity by thrombelastograph (TEG) platelet-mapping assay would be a powerful predictor of recurrent cardiovascular ischemic events.
Objective
This study sought to determine an integrate results evaluated by CYP2C19genotyping combined with platelet reactivity by TEG for enhanced prediction of major adverse cardiovascular events in Chinese patients undergoing coronary stenting with clopidogrel.
Methods
1104Chinese patients undergoing coronary stenting were enrolled in a single-center registry. CYP2C19genotyping (s4244285and rs4986893) were detected by the improved multiple ligase detection reaction. Platelet function testing were performed by thrombelastograph platelet-mapping assay. High on-treatment platelet reactivity (HTPR) was defined as cutoff values of ADP inhibition≤30%assessed by the TEG. Major adverse cardiovascular events (MACE) included the composite of all-cause death, nonfatal myocardial infarction, target vessel revascularization, or stent thrombosis. The follow-up period was12months.
Results
47patients (4.3%) had major adverse cardiovascular events. In the multivariate Cox regression analysis, carriers of CYP2C19loss-of-function alleles (*1/*2,*1/*3,*2/*2,*2/*3, and*3/*3) were increased nearly2.2-fold risk of MACE compared with noncarriers (HR:2.195,95%CI:1.035-4.658, P=0.04); HTPR were increased almost2.2-fold risk of MACE compared with normal on-treatment platelet reactivity (HR:2.218,95%CI:1.131-4.351, P=0.02). In the multivariate Cox regression analysis after an integrate results evaluated by CYP2C19genotyping combined with platelet reactivity by
TEG,2positive results (carriers of CYP2C19loss-of-function alleles and HTPR) were significantly increased almost3.8-fold of the risk of MACE compared with0positive results (noncarriers of CYP2C19loss-of-function alleles and normal on-treatment platelet reactivity)(HR:3.777,95%CI:1.508-9.461, P=0.005). Adding the integrate results to conventional clinical predictors improved prediction trend for1-year MACE as measured by the area under the ROC curve (AUC, from0.67to0.73; P=0.074), and the net reclassification improvement (NRI=27.7%; P=0.003)/integrated discrimination improvement (IDI=0.016; P=0.013).
Conclusions
The integrate results evaluated by CYP2C19genotyping combined with platelet reactivity by TEG is an independent and additive predictor of1-year MACE in Chinese patients undergoing stenting with clopidogrel, which is better than the either single testing (CYP2C19genotyping or platelet function testing).
氯吡格雷抑制血小板聚集具有个体差异性。研究发现部分患者使用氯吡格雷后仍有死亡、心肌梗死、中风或支架内血栓形成等严重不良缺血心血管事件发生,该现象称之为氯吡格雷低反应性。遗传因素是氯吡格雷低反应性的发生机制之一。目前尚不明确国人冠心病患者氯吡格雷代谢通路上相关基因的功能多态性位点与服用氯吡格雷后的血小板功能及不良临床预后的相关性。
研究目的
本研究拟验证国人冠心病患者氯吡格雷代谢通路上相关基因(ABCB1、CYP2C19、CYP3A、CYP3A5和口P2Y12)的功能多态性位点与服用氯吡格雷后的血小板功能及不良临床预后的相关性。
对象和方法
2012年1月到2013年2月入选收住我院拟行经皮冠状动脉介入治疗并置入支架的冠心病患者1408例。多重高温连接酶检测反应技术检测ABCB1、CYP2C19、 CYP3A4、CYP3A5和P2Y12基因上的15个功能多态性位点。血栓弹力图检测支架置入术后服用氯吡格雷24小时以内的血小板功能。所有入选患者均正规服用氯吡格雷12个月,并进行为期一年的临床随访。主要终点事件是指严重不良心血管事件,包括死亡、非致死性心肌梗死、靶血管血运重建或支架内血栓形成等复合终点事件；次要终点事件是指支架置入术后一年随访期间的死亡、非致死性心肌梗死、靶血管血运重建和支架内血栓形成。
研究结果
本研究入选国人冠心病患者携带CYP2C19功能缺失等位基因(*2和*3)的频率高达59.3%。携带两个CYP2C19功能缺失等位基因的患者与携带一个CYP2C19功能缺失等位基因或未携带CYP2C19功能缺失等位基因的患者相比,服用氯吡格雷后的血小板抑制率最低(44.6±31.1vs.52.0±30.0vs.55.4±30.5;P=0.001)。62位(4.4%)患者支架置入术后一年随访期间发生严重不良心血管事件。携带两个CYP2C19功能缺失等位基因的患者与携带一个CYP2C19功能缺失等位基因或未携带CYP2C19功能缺失等位基因的患者相比,严重不良心血管事件的发生率最高(7.5%vs.4.9%vs.2.8%；P=0.016)。多变量Cox回归分析发现：携带两个CYP2C19功能缺失等位基因的患者与未携带CYP2C19功能缺失等位基因的患者相比,支架置入术后一年随访期间严重不良心血管事件的发生率升高近3倍(HR=2.962；95%CI：1.426-6.152；P=0.004)：携带一个CYP2C19功能缺失等位基因的患者与未携带CYP2C19功能缺失等位基因的患者相比,严重不良缺血心血管事件的发生率没有明显升高(HR=1.833；95%CI：0.986-3.406；P=0.055)。氯吡格雷代谢通路上其他基因(ABCB1、CYP3A4、CYP3A5、和P2Y12)的功能多态性位点与国人冠心病患者服用氯吡格雷后的血小板反应性和支架置入术后一年随访期间严重不良心血管事件无明显相关性(P>0.05)。结论
携带两个CYP2C19功能缺失等位基因的国人冠心病患者与服用氯吡格雷后的血小板功能和支架置入术后一年随访期间的严重不良心血管事件有明确相关性；携带两个CYP2C19功能缺失等位基因是国人冠心病患者支架置入术后一年随访期间严重不良心血管事件的独立预测因素；氯吡格雷代谢通路上其他基因(ABCB1、CYP3A4、CYP3A5和P2Y12)的功能多态性位点与国人冠心病患者服用氯吡格雷后的血小板功能和支架置入术后一年随访期间严重不良心血管事件无显著相关性。
研究背景
研究证实服用抗血小板药物后的残存血小板高反应性可能与不良的临床预后有相关性。血小板功能检测方法是评价冠心病患者体内血小板活性和服用抗血小板药物后残存血小板反应性的实验室检测手段。目前血小板功能检测方法众多,例如光学比浊法,血栓弹力图,VerifyNow快速分析仪,活化舒血管磷蛋白磷酸化的检测等。哪种检测方法能更为准确特异的反应血小板功能和预测临床预后结果尚无明确结论,尤其是中国冠心病患者服用氯吡格雷后的血小板高反应性更无统一的诊断标准。
研究目的
本研究拟比较光学比浊法和血栓弹力图两种方法检测服用氯吡格雷后血小板高反应性的相关性及探讨对国人冠心病患者支架置入术后不良临床预后的预测价值。
对象和方法
2012年1月到2013年2月入选收住我院已行经皮冠状动脉介入治疗并置入支架的冠心病患者789例。服用氯吡格雷24小时以内,所有患者均采用光学比浊法和血栓弹力图两种方法检测血小板功能。所有入选患者支架置入术后均进行为期一年的临床随访。严重不良心血管事件是指支架置入术后一年随访期间死亡、非致死性心肌梗死、靶血管血运重建或支架内血栓形成等复合终点事件。
研究结果
支架置入术后一年随访期间,有32例患者(4.1%)发生严重不良心血管事件,其中有5例发生非致死性心肌梗死,3例患者发生支架内血栓,26例患者行靶血管血运重建。光学比浊法和血栓弹力图两种方法检测服用氯吡格雷后的残余血小板反应有相关性(Spearman r=0.733,P<0.001)。ROC曲线分析表明,支架置入术后一年的随访期间,光学比浊法(曲线下面积：0.677；95%可信区间：0.643-0.710；P=0.0009)和血栓弹力图(曲线下面积：0.684；95%可信区间：0.650-0.716；P=0.0001)两种检测方法均能一定程度的预测中国冠心病患者支架置入术后的严重不良心血管事件。光学比浊法评估服用氯吡格雷后血小板高反应性的患者严重不良心血管事件的发生率较血小板正常反应的患者明显升高(7.4%vs.2.7%；P=0.003)；血栓弹力图评估服用氯吡格雷后血小板高反应性的患者严重不良心血管事件的发生率较血小板正常反应的患者亦明显升高(6.7%vs.2.6%；P=0.005)。Kaplan-Meier分析表明,光学比浊法或血栓弹力图诊断为服用氯吡格雷后血小板高反应性的患者与血小板正常反应的患者相比,支架置入术后一年随访期间严重不良心血管事件的发生率明显升高(HR：2.752,95%CI：1.360-5.569,P=0.002；或HR：2.601；95%CI：1.279-5.290,P=0.005)
结论
光学比浊法和血栓弹力图两种血小板功能检测方法检测国人冠心病患者支架置入术后服用氯吡格雷的血小板功能,相关性较好；两种血小板功能检测方法均能一定程度上预测支架置入术后服用氯吡格雷的血小板高反应性患者发生严重不良心血管事件的风险明显升高。
研究背景
支架置入术后服用氯吡格雷的冠心病患者,是否应该常规检测CYP2C19基因分型和血小板功能以评估其临床预后尚不明确。本研究假设：整合CYP2C19基因分型和血小板功能检测两项结果是支架置入术后再发不良缺血心血管事件强有力的预测因素。
研究目的
本研究拟探讨CYP2C19基因分型联合血小板功能检测的两项结果预测国人冠心病患者支架置入术后一年随访期间的严重不良心血管事件。
对象和方法
2012年1月到2013年2月入选收住我院拟行经皮冠状动脉介入治疗并置入支架的冠心病患者1104例。多重高温连接酶检测反应技术进行CYP2C19基因分型(rs4244285和rs4986893)。服用氯吡格雷24小时以内,血栓弹力图检测入选患者的血小板功能。服用氯吡格雷后血小板高反应性定义为血栓弹力图检测二磷酸腺苷诱导的血小板抑制率≤30%。所有入选患者均正规服用氯吡格雷一年,并进行为期一年的临床随访。严重不良心血管事件包括死亡,非致死性心肌梗死,靶血管血运重建或支架内血栓形成等复合终点事件。
研究结果
47例(4.3%)患者支架置入术后一年随访期间发生严重不良心血管事件。多变量Cox回归模型分析CYP2C19基因分型的结果显示：CYP2C19功能缺失等位基因携带者(*1/*2、*1/*3、*2/*2、*2/*3和*3/*3)与未携带CYP2C19功能缺失等位基因的患者相比,支架置入术后一年随访期间严重不良心血管事件的发生风险升高近2.2倍(HR：2.195,95%CI：1.035-4.658,P=0.04)。多变量Cox回归模型分析服用氯吡格雷后的血小板功能,结果表明：服用氯吡格雷后血小板高反应性的患者与血小板正常反应的患者相比,支架置入术后一年随访期间严重不良心血管事件的发生风险也升高2.2倍左右(HR：2.218,95%CI：1.131-4.351,P=0.02)。通过多变量Cox回归模型分析CYP2C19基因分型联合血小板功能检测两项结果显示：携带CYP2C19功能缺失等位基因且服用氯吡格雷后血小板仍呈高反应性的患者,即2个阳性结果与无阳性结果(未携带CYP2C19功能缺失等位基因且服用氯吡格雷后血小板正常反应)的患者相比,PCI术后一年随访期间严重不良心血管事件(死亡非致死性心肌梗死、靶血管血运重建或支架内血栓形成等复合终点事件)的发生率升高近3.8倍(HR：3.777,95%CI：1.508-9.461,P=0.005)。CYP2C19基因分型联合血小板功能检测两项结果加入常规临床预测模型后,ROC曲线评估国人冠心病患者支架置入术后一年随访期间严重不良心血管事件的预测能力有所升高(AUC,from0.67to0.73；P=0.074),全部患者的净重新分类指数高达27.7%(P=0.003)整体鉴别指数是0.016(P=0.013)
结论
CYP2C19基因分型联合血小板功能检测均呈阳性结果的国人冠心病患者,支架置入术后一年随访期间严重不良心血管事件的发生率最高；CYP2C19基因分型联合血小板功能检测均呈阳性结果者,较单一CYP2C19基因分型或血小板功能检测,能更有效的预测国人冠心病患者PCI术后一年随访期间的严重不良心血管事件。
Background
Several studies have demonstrated wide inter-individual variability in the pharmacodynamic response to clopidogrel. Observational studies have linked a poor pharmacodynamic response to cardiovascular events after percutaneous coronary intervention (PCI), including death, recurrent myocardial infarction, stroke, or stent thrombosis. Genetic factors were considered as one of the mechanisms for clopidogrel hyporesposiveness. Effect of the ABCB1, CYP2C19, CYP3A4, CYP3A5, and P2Y12variants on platelet reactivity and clinical outcomes of clopidogrel has not been reported in Chinese patients undergoing PCI.
Objectives
The aim of this study was to investigate the effect of the ABCB1, CYP3A4, CYP3A5, and P2Y12variants on clopidogrel pharmacodynamics and clinical outcomes in these patients.
Methods
1408patients undergoing stent implantation were enrolled in a single-center registry. The ABCB1, CYP2C19, CYP3A4, CYP3A5, and P2Y12genotypes were detected by the improved multiple ligase detection reaction, and the antiplatelet effect of clopidogrel were assessed by thrombelastography. Primary clinical endpoint was defined as major adverse cardiovascular events (MACE), which included the composite of all-cause death, nonfatal myocardial infarction, target vessel revascularization, or stent thrombosis. The secondary clinical endpoints were all-cause death, nonfatal myocardial infarction, target vessel revascularization, and stent thrombosis during12-month follow-up.
Results
The carriage of the CYP2C19loss-of-function alleles was relatively high (59.3%).62(4.4%) patients had MACE during12-month follow-up. The lowest risk of response to clopidogrel (55.4±30.5vs.52.0±30.0vs.44.6±31.1; P=0.001) and the highest incidence of MACE (2.8%vs.4.9%vs.7.5%; P=0.016) increased with the number of CYP2C19loss-of-function alleles. In the multivariate Cox regression analysis, two CYP2C19LOF alleles (HR=2.962,95%CI:1.426-6.152, P=0.004) were associated with MACE compared with noncarriers; the carriers of one CYP2C19LOF allele (HR=1.833;95%CI:0.986-3.406; P=0.055) were not associated with MACE compared with noncarriers. However, there were no significant differences in clopidogrel pharmacodynamics and adverse ischemic events across the ABCB1, CYP3A4, CYP3A5and P2Y12genotype groups (P>0.05).
Conclusions
The CYP2C19loss-of-function alleles had a gene dose effect on the clopidogrel pharmacodynamics and major adverse cardiovascular events in our population. The carrage of two CYP2C19LOF alleles was an independent predictor of major adverse cardiovascular events in patients undergoing PCI during follow-up period. The antiplatelet effect and adverse clinical outcomes of clopidogrel were not significantly influenced by ABCB1, CYP3A4, CYP3A5and P2Y12genotype in these patients.
Background
Patients exhibiting heightened platelet reactivity to adenosine diphosphate (ADP) might be at increased risk for recurrent ischemic events after coronary stenting. Several platelet function tests are currently used to measure responsiveness to antiplatelet therapy.However, which test can be best to detect platelet function specifically and predict clincial outcomes was still uncertain. High on-treatment platelet reactivity of Chinese patients is still no uniform diagnostic criteria.
Objectives
The aim of our study was to whether patients receiving clopidogrel undergoing stenting who display high on-treatment platelet reactivity measured by light transmittance aggregometry (LTA) and thrombelastography (TEG) will be at increased risk for poststenting ischemic events.
Methods
Prospective, observational, single-center study of789Chinese patients underwent stent implantation. This study was investigated the correlations between the2tests (LTA and TEG) and performed receiver operating characteristic curve (ROC) analysis for major adverse cardiovascular events (MACE), a composite of death, myocardial infarction (MI), stent thrombosis, or target vessel revascularization, at1-year follow-up.
Results
Major adverse cardiovascular events occurred in32patients (4.1%), including5patients with recurrent MI,3patients with stent thrombosis, and26patients with target vessel revascularization. Correlations were strong between the2tests in the adenosine diphosphate induced platelet reactivity (Spearman r=0.733, P<0.001). ROC-curve analysis demonstrated that LTA (area under the curve [AUC],0.677;95%confidence interval [CI],0.643-0.710; P=0.0009), and TEG assay (AUC,0.684;95%CI,0.650-0.716; P=0.0001) had moderate ability to discriminate between patients with and without MACE at1-year follow-up. MACE occurred more frequently in patients with high on-treatment platelet reactivity (HTPR) when assessed by LTA (7.4%vs.2.7%; P=0.003), and by TEG (6.7%vs.2.6%; P=0.005). Kaplan-Meier analysis demonstrated that HTPR based on the LTA and modified TEG was associated with almost4-fold increased risk of MACE at1-year follow-up (HR:2.752,95%CI:1.360-5.569, P=0.005; HR:2.601;95%CI:1.279-5.290, P=0.008; respectively).
Conclusions The ADP-induced platelet aggregation by LTA and TEG showed a strong correlation. Hypo-responsiveness to clopidogrel measured by light transmittance aggregometry, and modified thrombelastography were significantly associated with MACE in Chinese patients undergoing stenting. However, the predictive accuracy of these two tests was moderate.
Background
Routine assessment of CYP2C19genotyping or platelet function after clopidogrel, which can be used to risk-stratify patients with coronary artery disease receiving stenting implantation, is still debated. We hypothesized that an aggregate risk evaluated by CYP2C19genotyping combined with platelet reactivity by thrombelastograph (TEG) platelet-mapping assay would be a powerful predictor of recurrent cardiovascular ischemic events.
Objective
This study sought to determine an integrate results evaluated by CYP2C19genotyping combined with platelet reactivity by TEG for enhanced prediction of major adverse cardiovascular events in Chinese patients undergoing coronary stenting with clopidogrel.
Methods
1104Chinese patients undergoing coronary stenting were enrolled in a single-center registry. CYP2C19genotyping (s4244285and rs4986893) were detected by the improved multiple ligase detection reaction. Platelet function testing were performed by thrombelastograph platelet-mapping assay. High on-treatment platelet reactivity (HTPR) was defined as cutoff values of ADP inhibition≤30%assessed by the TEG. Major adverse cardiovascular events (MACE) included the composite of all-cause death, nonfatal myocardial infarction, target vessel revascularization, or stent thrombosis. The follow-up period was12months.
Results
47patients (4.3%) had major adverse cardiovascular events. In the multivariate Cox regression analysis, carriers of CYP2C19loss-of-function alleles (*1/*2,*1/*3,*2/*2,*2/*3, and*3/*3) were increased nearly2.2-fold risk of MACE compared with noncarriers (HR:2.195,95%CI:1.035-4.658, P=0.04); HTPR were increased almost2.2-fold risk of MACE compared with normal on-treatment platelet reactivity (HR:2.218,95%CI:1.131-4.351, P=0.02). In the multivariate Cox regression analysis after an integrate results evaluated by CYP2C19genotyping combined with platelet reactivity by
TEG,2positive results (carriers of CYP2C19loss-of-function alleles and HTPR) were significantly increased almost3.8-fold of the risk of MACE compared with0positive results (noncarriers of CYP2C19loss-of-function alleles and normal on-treatment platelet reactivity)(HR:3.777,95%CI:1.508-9.461, P=0.005). Adding the integrate results to conventional clinical predictors improved prediction trend for1-year MACE as measured by the area under the ROC curve (AUC, from0.67to0.73; P=0.074), and the net reclassification improvement (NRI=27.7%; P=0.003)/integrated discrimination improvement (IDI=0.016; P=0.013).
Conclusions
The integrate results evaluated by CYP2C19genotyping combined with platelet reactivity by TEG is an independent and additive predictor of1-year MACE in Chinese patients undergoing stenting with clopidogrel, which is better than the either single testing (CYP2C19genotyping or platelet function testing).
引文
[I]CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel verse aspirin in patients at risk for ischemic events (CAPRIE). Lancet,1996,348(9038): 1329-1339.
[2]YusufS, ZhaoF, Mehta SR, et al. Efects of clopidogrel in addition to aspirin in pa tients with acute coronary syndromes without ST-segment elevation. N Engl J Med, 2001,345(7):494-502.
[3]Sebatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and flbrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med,2005,352(12):1179-1189.
[4]Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Variability in individual responsiveness to clopidogrel:Clinical implications, management, and future perspectives. J Am Coll Cardiol.2007;49:1505-1516.
[5]Ong AT, Hoye A, Aoki J, et al. Thirty day incidence and six month clinical outcome of thrombotic stent occlusion after bare metal, sirolimus, or paclitaxel stent implantation. J Am Coll Cardiol,2005,45(6):947-953.
[6]Lakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug eluting stents. JAMA,2005,293(17): 2126-2130.
[7]Kazui M, Nishiya Y, Ishizuka T, et al. Identification of the human cytochrome p450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos.2010;38:92-99.
[8]Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med.2009; 360:363-375.
[9]Mega JL, Close SL, Wiviott SD, et al. Genetic variants in abcbl and cyp2cl9 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the triton-timi 38 trial:A pharmacogenetic analysis. Lancet.2010;376:1312-1319.
[10]Jaitner J, Morath T, Byrne RA, et al. No association of abcbl c3435t genotype with clopidogrel response or risk of stent thrombosis in patients undergoing coronary stenting. Circ Cardiovasc Interv.2012;5:82-88.
[11]Luo M, Li J, Xu X, et al. Abcbl c3435t polymorphism and risk of adverse clinical events in clopidogrel treated patients:A meta-analysis. Thromb Res. 2012;129:754-759.
[12]Rideg O, Komocsi A, Magyarlaki T, et al. Impact of genetic variants on post-clopidogrel platelet reactivity in patients after elective percutaneous coronary intervention. Pharmacogenomics.2011;12:1269-1280.
[13]Staritz P, Kurz K, Stoll M, et al. Platelet reactivity and clopidogrel resistance are associated with the h2 haplotype of the p2yl2-adp receptor gene. Int J Cardiol. 2009;133:341-345.
[14]von Beckerath N, von Beckerath O, Koch W, et al. P2y12 gene h2 haplotype is not associated with increased adenosine diphosphate-induced platelet aggregation after initiation of clopidogrel therapy with a high loading dose. Blood Coagul Fibrinolysis. 2005;16:199-204.
[15]Cuisset T, Frere C, Quilici J, et al. Role of the t744c polymorphism of the p2y12 gene on platelet response to a 600-mg loading dose of clopidogrel in 597 patients with non-st-segment elevation acute coronary syndrome. Thromb Res.2007;120: 893-899.
[16]Mega JL, Simon T, Collet JP, et al. Reduced-function cyp2c19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for pci:A meta-analysis. JAMA.2010;304:1821-1830.
[17]Giusti B, Gori AM, Marcucci R, et al. Relation of cytochrome p450 2c 19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis. Am J Cardiol.2009; 103:806-811.
[18]Sibbing D, Stegherr J, Latz W, et al. Cytochrome p450 2c19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. Eur Heart J.2009;30:916-922.
[19]Man M, Farmen M, Dumaual C, et al. Genetic variation in metabolizing enzyme and transporter genes:Comprehensive assessment in 3 major east asian subpopulations with comparison to caucasians and africans. J Clin Pharmacol.2010;50:929-940.
[20]Guidelines for percutaneous transluminal coronary angioplasty. A report of the American College of Cardiology/American Heart Association Task Force on assessment of diagnostic and therapeuitic cardiovascular procedures (subcommittee on percutaneous transluminal coronary argioplasty). Circulation,1988,78(2): 486-502.
[21]Levine GN, Bates ER, Blankenship JC, et al.2011 accf/aha/scai guideline for percutaneous coronary intervention:A report of the american college of cardiology foundation/american heart association task force on practice guidelines and the society for cardiovascular angiography and interventions. Catheter Cardiovasc Interv. 2013;82:E266-355.
[22]Levine GN, Bates ER, Blankenship JC, et al.2011 accf/aha/scai guideline for percutaneous coronary intervention:A report of the american college of cardiology foundation/american heart association task force on practice guidelines and the society for cardiovascular angiography and interventions. Circulation. 2011;124:e574-651.
[23]Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: A case for standardized definitions. Circulation.2007;115:2344-2351.
[24]Whitworth JA,2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens.2003, 21(11):1983-1992.
[25]Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1:diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med,1998,15(7):539-553.
[26]Kato N, Sugiyama T, Morita H, et al. Genetic analysis of the atrial natriuretic peptide gene in essential hypertension. Clin Sci (Lond).2000;98:251-258.
[27]Steinhubl SR, Berger PB, Mann JT, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention:a randomized controlled trial. JAMA,2002,288(19):2411-2420.
[28]Gerschutz GP, Bhatt DL, et al. The Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) study:to what extent should the results be generalizable? Am Heart J,2003,145(4):595-601.
[29]Taubert D, von Beckerath N, Grimberg G, et al. Impact of p-glycoprotein on clopidogrel absorption. Clin Pharmacol Ther.2006;80:486-501.
[30]Lee JM, Park S, Shin DJ, et al. Relation of genetic polymorphisms in the cytochrome p450 gene with clopidogrel resistance after drug-eluting stent implantation in koreans. Am J Cardiol.2009; 104:46-51.
[31]Goldstein JA, Ishizaki T, Chiba K, et al. Frequencies of the defective cyp2c19 alleles responsible for the mephenytoin poor metabolizer phenotype in various oriental, caucasian, saudi arabian and american black populations. Pharmacogenetics. 1997;7:59-64.
[32]Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Contribution of gene sequence variations of the hepatic cytochrome p450 3a4 enzyme to variability in individual responsiveness to clopidogrel. Arterioscler Thromb Vasc Biol.2006;26:1895-1900.
[33]Kreutz RP, Owens J, Jin Y, et al. Cytochrome p450 3a4*22, ppar-alpha, and arnt polymorphisms and clopidogrel response. Clin Pharmacol.2013;5:185-192.
[34]Suh JW, Koo BK, Zhang SY, et al. Increased risk of atherothrombotic events associated with cytochrome p450 3a5 polymorphism in patients taking clopidogrel. CMAJ.2006; 174:1715-1722.
[35]Park KW, Kang J, Park JJ, et al. Amlodipine, clopidogrel and cyp3a5 genetic variability:Effects on platelet reactivity and clinical outcomes after percutaneous coronary intervention. Heart.2012;98:1366-1372.
[36]Fontana P, Gaussem P, Aiach M, et al. P2y12 h2 haplotype is associated with peripheral arterial disease:A case-control study. Circulation.2003; 108:2971-2973.
[37]Ziegler S, Schillinger M, Funk M, et al. Association of a functional polymorphism in the clopidogrel target receptor gene, p2y12, and the risk for ischemic cerebrovascular events in patients with peripheral artery disease. Stroke. 2005;36:1394-1399.
[38]Preobrazhenskii DV, Sidorenko BA, Batyraliev TA, et al. Thienopyridines in the treatment and prevention of cardiovascular diseases. Part ii. Clinical pharmacology of clopidogrel. Kardiologiia.2009;49:88-96.
[39]Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Lack of association between the p2y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease. Thromb Res.2005;116:491-497.
[1]Gurbel PA, Bliden KP, Hayes KM, et al. Platelet activation in myocardial ischemic syndromes. Expert Rev Cardiovasc Ther.2004;2:535-545.
[2]Gurbel PA, Bliden KP, Samara W, et al. Clopidogrel effect on platelet reactivity in patients with stent thrombosis:Results of the crest study. J Am Coll Cardiol. 2005;46:1827-1832.
[3]Levine GN, Bates ER, Blankenship JC, et al.2011 accf/aha/scai guideline for percutaneous coronary intervention:A report of the american college of cardiology foundation/american heart association task force on practice guidelines and the society for cardiovascular angiography and interventions. Catheter Cardiovasc Interv. 2013;82:E266-355.
[4]Anderson JL, Adams CD, Antman EM, et al.2011 accf/aha focused update incorporated into the acc/aha 2007 guidelines for the management of patients with unstable angina/non-st-elevation myocardial infarction:A report of the american college of cardiology foundation/american heart association task force on practice guidelines. Circulation.2011;123:e426-579.
[5]Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation.2004;109:3171-3175.
[6]Price MJ, Endemann S, Gollapudi RR, et al. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J.2008;29:992-1000.
[7]Bonello L, Camoin-Jau L, Arques S, et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance:A multicenter randomized prospective study. J Am Coll Cardiol.2008;51:1404-1411.
[8]Bliden KP, DiChiara J, Tantry US, et al. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention:Is the current antiplatelet therapy adequate? J Am Coll Cardiol. 2007;49:657-666.
[9]Angiolillo DJ, Capranzano P, Desai B, et al. Impact of p2y(12) inhibitory effects induced by clopidogrel on platelet procoagulant activity in type 2 diabetes mellitus patients. Thromb Res.2009;124:318-322.
[10]Gurbel PA, Bliden KP, Guyer K, et al. Platelet reactivity in patients and recurrent events post-stenting:Results of the prepare post-stenting study. J Am Coll Cardiol, 2005;46:1820-1826.
[11]Kim IS, Jeong YH, Kang MK, et al. Correlation of high post-treatment platelet reactivity assessed by light transmittance aggregometry and the verifynow p2y12 assay. J Thromb Thrombolysis.2010;30:486-495.
[12]Kim IS, Jeong YH, Tantry US, et al. Relation between the vasodilator-stimulated phosphoprotein phosphorylation assay and light transmittance aggregometry in east asian patients after high-dose clopidogrel loading. Am Heart J.2013;166:95-103.
[13]Guidelines for percutaneous transluminal coronary angioplasty. A report of the American College of Cardiology/American Heart Association Task Force on assessment of diagnostic and therapeuitic cardiovascular procedures (subcommittee on percutaneous transluminal coronary argioplasty). Circulation,1988,78(2): 486-502.
[14]Levine GN, Bates ER, Blankenship JC, et al.2011 accf/aha/scai guideline for percutaneous coronary intervention:A report of the american college of cardiology foundation/american heart association task force on practice guidelines and the society for cardiovascular angiography and interventions. Circulation. 2011;124:e574-651.
[15]Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: A case for standardized definitions. Circulation.2007; 115:2344-2351.
[16]Whitworth JA,2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens.2003, 21(11):1983-1992.
[17]Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1:diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med,1998,15(7):539-553.
[18]Kato N, Sugiyama T, Morita H, et al. Genetic analysis of the atrial natriuretic peptide gene in essential hypertension. Clin Sci (Lond).2000;98:251-258.
[19]Gabriel SA, Beteli CB, Tanighuchi RS, et al. Aspirin resistance and atherothrombosis. Rev Bras Cir Cardiovasc.2007;22:96-103.
[20]Hochholzer W, Trenk D, Bestehorn HP, et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol.2006;48:1742- 1750.
[21]Gurbel PA, Bliden KP, Samara W, et al. Clopidogrel effect on platelet reactivity in patients with stent thrombosis:Results of the crest study. J Am Coll Cardiol. 2005;46:1827-1832.
[22]Breet NJ, van Werkum JW, Bouman HJ, et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA.2010;303:754-762.
[23]Tantry US, Bonello L, Aradi D, et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol.2013;62:2261-2273.
[24]Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Variability in individual responsiveness to clopidogrel:Clinical implications, management, and future perspectives. J Am Coll Cardiol.2007;49:1505-1516.
[25]Stein B, Weintraub WS, Gebhart SP, et al. Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty. Circulation. 1995;91:979-989.
[26]Song YB, Hahn JY, Gwon HC, et al. A high loading dose of clopidogrel reduces myocardial infarct size in patients undergoing primary percutaneous coronary intervention:A magnetic resonance imaging study. Am Heart J.2012;163:500-507.
[27]Tantry US, Bliden KP, Suarez TA, et al. Hypercoagulability, platelet function, inflammation and coronary artery disease acuity:Results of the thrombotic risk progression (trip) study. Platelets.2010;21:360-367.
[28]Park KW, Kang SH, Park JJ, et al. Adjunctive cilostazol versus double-dose clopidogrel after drug-eluting stent implantation:The host-assure randomized trial (harmonizing optimal strategy for treatment of coronary artery stenosis-safety & effectiveness of drug-eluting stents & anti-platelet regimen). JACC Cardiovasc Interv. 2013;6:932-942.
[29]Park DW, Yun SC, Lee JY, et al. C-reactive protein and the risk of stent thrombosis and cardiovascular events after drug-eluting stent implantation. Circulation. 2009;120:1987-1995.
[30]Albert MA, Glynn RJ, Buring J, et al. C-reactive protein levels among women of various ethnic groups living in the united states (from the women's health study). Am J Cardiol.2004;93:1238-1242.
[31]Gurbel PA, Bliden KP, Navickas IA, et al. Adenosine diphosphate-induced platelet-fibrin clot strength:A new thrombelastographic indicator of long-term poststenting ischemic events. Am Heart J.2010;160:346-354.
[1]YusufS, Zhao F, Mehta SR, et al. Efects of clopidogrel in addition to aspirin in pa tients with acute coronary syndromes without ST-segment elevation. N Engl J Med, 2001,345(7):494-502.
[2]Sebatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and flbrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med,2005,352(12):1179-1189.
[3]Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Variability in individual responsiveness to clopidogrel:Clinical implications, management, and future perspectives. J Am Coll Cardiol.2007;49:1505-1516.
[4]Ong AT, Hoye A, Aoki J, et al. Thirty day incidence and six month clinical outcome of thrombotic stent occlusion after bare metal, sirolimus, or paclitaxel stent implantation. J Am Coll Cardiol,2005,45(6):947-953.
[5]Lakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug eluting stents. JAMA,2005,293(17): 2126-2130.
[6]Man M, Farmen M, Dumaual C, et al. Genetic variation in metabolizing enzyme and transporter genes:Comprehensive assessment in 3 major east asian subpopulations with comparison to Caucasians and africans. J Clin Pharmacol.2010;50:929-940.
[7]Goldstein JA, Ishizaki T, Chiba K, et al. Frequencies of the defective cyp2c19 alleles responsible for the mephenytoin poor metabolizer phenotype in various oriental, Caucasian, saudi arabian and american black populations. Pharmacogenetics. 1997;7:59-64.
[8]Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med.2009; 360:363-375.
[9]Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med.2009;360:354-362.
[10]Tang XF, Wang J, Zhang JH, et al. Effect of the cyp2c192 and 3 genotypes, abcbl c3435t and ponl q192r alleles on the pharmacodynamics and adverse clinical events of clopidogrel in Chinese people after percutaneous coronary intervention. Eur J Clin Pharmacol.2013;69:1103-1112.
[11]Price MJ, Endemann S, Gollapudi RR, et al. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J.2008;29:992-1000.
[12]Brar SS, ten Berg J, Marcucci R, et al. Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data. J Am Coll Cardiol,2011;58::1945-54.
[13]Hamm CW, Bassand JP, Agewall S, et al. Esc guidelines for the management of acute coronary syndromes in patients presenting without persistent st-segment elevation:The task force for the management of acute coronary syndromes (acs) in patients presenting without persistent st-segment elevation of the european society of cardiology (esc). Eur Heart J.2011;32:2999-3054.
[14]Levine GN, Bates ER, Blankenship JC, et al.2011 accf/aha/scai guideline for percutaneous coronary intervention:A report of the american college of cardiology foundation/american heart association task force on practice guidelines and the society for cardiovascular angiography and interventions. Catheter Cardiovasc Interv. 2013;82:E266-355.
[15]O'Gara PT, Kushner FG, Ascheim DD, et al.2013 accf/aha guideline for the management of st-elevation myocardial infarction:A report of the american college of cardiology foundation/american heart association task force on practice guidelines. Circulation.2013;127:e362-425.
[16]Guidelines for percutaneous transluminal coronary angioplasty. A report of the American College of Cardiology/American Heart Association Task Force on assessment of diagnostic and therapeuitic cardiovascular procedures (subcommittee on percutaneous transluminal coronary argioplasty). Circulation,1988,78(2): 486-502.
[17]Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: A case for standardized definitions. Circulation.2007; 115:2344-2351.
[18]Whitworth JA,2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens.2003, 21(11):1983-1992.
[19]Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1:diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med,1998,15(7):539-553.
[20]中国成人血脂异常防治指南制订联合委员会。中国成人血脂异常防治指南。中华心血管病杂志,2007,35(5)：390-413.
[21]叶任高,陆再英。内科学[M]。第6版,北京：人民卫生出版社,2005：558.
[22]Wang TY,Ou FS,Roe MT,et al.Incidence and prognostic significance ofthrombocytopenia developed during acute coronary syndrome in contemporaryclinical practice.Circulation.2009;119：2454-2462.
[23]Kato N,Sugiyama T,Morita H,et al.Genetic analysis of the atrial natriureticpeptide gene in essential hypertension.Clin Sci(Lond).2000；98：251-258.
[24]Bliden KP,DiChiara J,Tantry US,et al.Increased risk in patients with high plateletaggregation receiving chronic clopidogrel therapy undergoing percutaneous coronaryintervention：Is the current antiplatelet therapy adequate? J Am Coll Cardiol.2007;49：657-666.
[25]Pencina MJ,D'Agostino RB,Sr.,D'Agostino RB,et al.Evaluating the addedpredictive ability of a new marker：From area under the roc curve to reclassificationand beyond.Stat Med.2008；27：157-172；discussion 207-112.
[26]Kazui M,Nishiya Y,Ishizuka T,et al.Identification of the human cytochrome p450enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to itspharmacologically active metabolite.Drug Metab Dispos.2010；38：92-99.
[27]Shuldiner AR,O'Connell JR,Bliden KP,et al.Association of cytochrome p4502c19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.JAMA.2009;302：849-857.
[28]Scott SA,Sangkuhl K,Gardner EE,et al.Clinical pharmacogenetics implementationconsortium guidelines for cytochrome p450-2c19(cyp2c19)genotype andclopidogrel therapy.Clin Pharmacol Ther.2011；90：328-332.
[29]Mega JL,Simon T,Collet JP,et al.Reduced-function cyp2c19 genotype and risk ofadverse clinical outcomes among patients treated with clopidogrel predominantly forpci：A meta-analysis.JAMA.2010；304：1821-1830.
[30]Gurbel PA,Bliden KP,Navickas IA,et al.Adenosine diphosphate-inducedplatelet-fibrin clot strength：A new thrombelastographic indicator of long-termpoststenting ischemic events.Am Heart J.2010；160：346-354.
[31]Stone G W,Witzenbichler B,Weisz G,et al.Platelet reactivity and clinical outcomesafter coronary artery implantation of drug-eluting stents(adapt-des)：A prospectivemulticentre registry study.Lancet.2013；382：614-623.
[32]Breet NJ,van Werkum JW,Bouman HJ,et al.Comparison of platelet function testsin predicting clinical outcome in patients undergoing coronary stent implantation.JAMA.2010;303：754-762.
[33]Miller M,Kwiterovich PO,Jr.Isolated low hdl-cholesterol as an important risk factor for coronary heart disease. Eur Heart J.1990;11 Suppl H:9-14.
[34]Gotto AM, Jr., Brinton EA. Assessing low levels of high-density lipoprotein cholesterol as a risk factor in coronary heart disease:A working group report and update. JAm Coll Cardiol.2004;43:717-724.
[35]Lee PC, Kini AS, Ahsan C, et al. Anemia is an independent predictor of mortality after percutaneous coronary intervention. J Am Coll Cardiol.2004;44:541-546.
[36]Campo G, Parrinello G, Ferraresi P, et al. Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome. J Am Coll Cardiol.2011;57:2474-2483.
[37]Price MJ, Berger PB, Teirstein PS, et al. Standard-vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention:The gravitas randomized trial. JAMA.2011;305:1097-1105.
[1]Xiang YZ, Xia Y, Gao XM, et al. Platelet activation, and antiplatelet targets and agents:Current and novel strategies. Drugs.2008;68:1647-1664.
[2]Jennings LK, Saucedo JF. Antiplatelet and anticoagulant agents:Key differences in mechanisms of action, clinical application, and therapeutic benefit in patients with non-st-segment-elevation acute coronary syndromes. Curr Opin Cardiol. 2008;23:302-308.
[3]Levine GN, Bates ER, Blankenship JC, et al.2011 accf/aha/scai guideline for percutaneous coronary intervention:A report of the american college of cardiology foundation/american heart association task force on practice guidelines and the society for cardiovascular angiography and interventions. Catheter Cardiovasc Interv. 2013;82:E266-355.
[4]Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with st-segment elevation. N Engl J Med.2005;352:1179-1189.
[5]Serebruany VL, Steinhubl SR, Berger PB, et al. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol.2005;45:246-251.
[6]Gurbel PA, Bliden KP, Hiatt BL, et al. Clopidogrel for coronary stenting:response variability drug resistance and the effect of pretreatment platelet reactivity. Circulation,2003,107(23):2908-2913.
[7]Muller I, Besta F, Schulz C, et al. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost.2003;89:783-787.
[8]Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation.2004;109:3171-3175.
[9]Kazui M, Nishiya Y, Ishizuka T, et al. Identification of the human cytochrome p450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos.2010;38:92-99.
[10]Ding Z, Kim S, Dorsam RT, et al. Inactivation of the human p2y12 receptor by thiol reagents requires interaction with both extracellular cysteine residues, cys17 and cys270. Blood.2003;101:3908-391.
[11]Patrono C, Bachmann F, Baigent C, et al. [expert consensus document on the use of antiplatelet agents]. Rev Esp Cardiol.2004;57:963-980.
[12]Mehta SR, Yusuf S. The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme; rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease. Eur Heart J,2000,21(24):2033-41.
[13]Mehta S, Yusuf S, Peters R, P et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undrgoing percutaneous coronary intervention:The PCI-CURE study. Lancet,2001,358(9281):527-533.
[14]Chen ZM, Jiang LX, Chen YP, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction:randomised placebo-controlled trial. Lancet, 2005,366 (9497):1607-1621.
[15]Steinhubl SR, Berger PB, Mann JT, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention:a randomized controlled trial. JAMA,2002,288(19):2411-20.
[16]Barragan P, Bouvier JL, Roquebert PO, et al. Resistance to thienopyridines:clinieal detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phos-phorylation. Catheter Cardiovasc Interv,2003,59(3):295-302.
[17]Bliden KP, DiChiara J, Tantry US, et al. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention:Is the current antiplatelet therapy adequate? J Am Coll Cardiol. 2007;49:657-666.
[18]Breet NJ, van Werkum JW, Bouman HJ, et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA.2010;303:754-762.
[19]Bonello L, Tantry US, Marcucci R, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol.2010;56:919-933.
[20]Tantry US, Bonello L, Aradi D, et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol.2013;62:2261-2273.
[21]Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Variability in individual responsiveness to clopidogrel:Clinical implications, management, and future perspectives. J Am Coll Cardiol.2007;49:1505-1516.
[22]Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med.2009; 360:363-375.
[23]Mega JL, Close SL, Wiviott SD, et al. Genetic variants in abcbl and cyp2c19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the triton-timi 38 trial:A pharmacogenetic analysis. Lancet.2010;376:1312-1319.
[24]Jaitner J, Morath T, Byrne RA, et al. No association of abcbl c3435t genotype with clopidogrel response or risk of stent thrombosis in patients undergoing coronary stenting. Circ Cardiovasc Interv:2012;5:82-88.
[25]Tang XF, Wang J, Zhang JH, et al. Effect of the cyp2c192 and 3 genotypes, abcbl c3435t and ponl q192r alleles on the pharmacodynamics and adverse clinical events of clopidogrel in Chinese people after percutaneous coronary intervention. Eur J Clin Pharmacol.2013;69:1103-1112.
[26]Sim SC, Miller WL, Zhong XB, et al. Nomenclature for alleles of the cytochrome p450 oxidoreductase gene. Pharmacogenet Genomics.2009;19:565-566.
[27]Liang ZY, Han YL, Zhang XL, et al. The impact of gene polymorphism and high on-treatment platelet reactivity on clinical follow-up:Outcomes in patients with acute coronary syndrome after drug-eluting stent implantation. EuroIntervention. 2013;9:316-327.
[28]Mega JL, Simon T, Collet JP, et al. Reduced-function cyp2c19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for pci:A meta-analysis. JAMA.2010;304:1821-1830.
[29]Giusti B, Gori AM, Marcucci R, et al. Relation of cytochrome p450 2c19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis. Am J Cardiol.2009;103:806-811.
[30]Sibbing D, Stegherr J, Latz W, et al. Cytochrome p450 2c19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. Eur Heart J.2009;30:916-922.
[31]Eiselt R, Domanski TL, Zibat A, et al. Identification and functional characterization of eight cyp3a4 protein variants. Pharmacogenetics.2001;11:447-458.
[32]Liu YT, Hao HP, Liu CX, et al. Drugs as cyp3a probes, inducers, and inhibitors. Drug Metab Rev.2007;39:699-721.
[33]Lakhman SS, Ma Q, Morse GD. Pharmacogenomics of cyp3a:Considerations for hiv treatment. Pharmacogenomics.2009;10:1323-1339.
[34]Lau WC, Gurbel PA, Watkins PB, et al. Contribution of hepatic cytochrome p450 3a4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation. 2004;109:166-171.
[35]Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Contribution of gene sequence variations of the hepatic cytochrome p450 3a4 enzyme to variability in individual responsiveness to clopidogrel. Arterioscler Thromb Vase Biol.2006;26:1895-1900.
[36]Giusti B, Gori AM, Marcucci R, et al. Cytochrome p450 2c19 loss-of-function polymorphism, but not cyp3a4 ivs10+12g/a and p2y12 t744c polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients. Pharmacogenet Genomics.2007;17:1057-1064.
[37]Kreutz RP, Owens J, Jin Y, et al. Cytochrome p450 3a4*22, ppar-alpha, and arnt polymorphisms and clopidogrel response. Clin Pharmacol.2013;5:185-192.
[38]Suh JW, Koo BK, Zhang SY, et al. Increased risk of atherothrombotic events associated with cytochrome p450 3a5 polymorphism in patients taking clopidogrel. CMAJ.2006;174:1715-1722.
[39]Kim KA, Park PW, Park JY. Effect of cyp3a5*3 genotype on the pharmacokinetics and antiplatelet effect of clopidogrel in healthy subjects. Eur J Clin Pharmacol. 2008;64:589-597.
[40]Park KW, Kang J, Park JJ, et al. Amlodipine, clopidogrel and cyp3a5 genetic variability:Effects on platelet reactivity and clinical outcomes after percutaneous coronary intervention. Heart.2012;98:1366-1372.
[41]Fontana P, Gaussem P, Aiach M, et al. P2y12 h2 haplotype is associated with peripheral arterial disease:A case-control study. Circulation.2003;108:2971-2973.
[42]Staritz P, Kurz K, Stoll M, et al. Platelet reactivity and clopidogrel resistance are associated with the h2 haplotype of the p2yl2-adp receptor gene, Int J Cardiol. 2009;133:341-345.
[43]von Beckerath N, von Beckerath O, Koch W, et al. P2y12 gene h2 haplotype is not associated with increased adenosine diphosphate-induced platelet aggregation after initiation of clopidogrel therapy with a high loading dose. Blood Coagul Fibrinolysis. 2005;16:199-204.
[44]Cuisset T, Frere C, Quilici J, et al. Role of the t744c polymorphism of the p2y12 gene on platelet response to a 600-mg loading dose of clopidogrel in 597 patients with non-st-segment elevation acute coronary syndrome. Thromb Res.2007; 120: 893-899.
[45]Malek LA, Kisiel B, Spiewak M, et al. Coexisting polymorphisms of p2y12 and cyp2c19 genes as a risk factor for persistent platelet activation with clopidogrel. Circ J.2008;72:1165-1169.
[46]Tang XF, Zhang JH, Wang J, et al. Effects of coexisting polymorphisms of cyp2cl9 and p2yl2 on clopidogrel responsiveness and clinical outcome in patients with acute coronary syndromes undergoing stent-based coronary intervention. Chin Med J (Engl).2013;126:1069-1075.
[47]Giusti B, Gori AM, Marcucci R, et al. Role of glycoprotein ia gene polymorphisms in determining platelet function in myocardial infarction patients undergoing percutaneous coronary intervention on dual antiplatelet treatment. Atherosclerosis. 2008;196:341-348.
[48]Feher G, Koltai K, Alkonyi B, Papp E, Keszthelyi Z, Kesmarky G, Toth K. Clopidogrel resistance:Role of body mass and concomitant medications. Int J Cardiol 2007;120:188-192.
[49]Lev El, Patel RT, Maresh KJ, et al. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention:The role of dual drug resistance. J Am Coll Cardiol.2006;47:27-33.
[50]Frere C, Cuisset T, Quilici J, et al. Adp-induced platelet aggregation and platelet reactivity index vasp are good predictive markers for clinical outcomes in non-st elevation acute coronary syndrome. Thromb Haemost.2007;98:838-843.
[51]Jin HY, Yang TH, Kim DI, et al. High post-clopidogrel platelet reactivity assessed by a point-of-care assay predicts long-term clinical outcomes in patients with st-segment elevation myocardial infarction who underwent primary coronary stenting. Int J Cardiol.2013;167:1877-1881.
[52]Ades PA, Savage PD, Toth MJ, et al. The influence of obesity and consequent insulin resistance on coronary risk factors in medically treated patients with coronary disease. Int JObes (Lond).2008;32:967-974.
[53]Lepantalo A, Virtanen KS, Heikkila J, et al. Limited early antiplatelet effect of 300 mg clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions. Eur Heart J.2004;25:476-483.
[54]Gabriel SA, Beteli CB, Tanighuchi RS, et al. Aspirin resistance and atherothrombosis. Rev Bras Cir Cardiovasc.2007;22:96-103.
[55]Zhou L, Schmaier AH. Platelet aggregation testing in platelet-rich plasma: Description of procedures with the aim to develop standards in the field. Am J Clin Pathol.2005;123:172-183.
[56]Hobson AR, Petley GW, Dawkins KD, et al. A novel fifteen minute test for assessment of individual time-dependent clotting responses to aspirin and clopidogrel using modified thrombelastography. Platelets.2007;18:497-505.
[57]Malinin A, Pokov A, Spergling M, et al. Monitoring platelet inhibition after clopidogrel with the verifynow-p2yl2(r) rapid analyzer:The verify thrombosis risk assessment (veritas) study. Thromb Res.2007; 119:277-284.
[58]Jakubowski JA, Li YG, Small DS, et al. A comparison of the verifynow p2y12 point-of-care device and light transmission aggregometry to monitor platelet function with prasugrel and clopidogrel:An integrated analysis. J Cardiovasc Pharmacol. 2010;56:29-37.
[59]Jilma B. Platelet function analyzer (pfa-100):A tool to quantify congenital or acquired platelet dysfunction. J Lab Clin Med.2001; 138:152-163.
[60]Lakkis NM, George S, Thomas E, et al. Use of ichor-platelet works to assess platelet function in patients treated with gp iib/iiia inhibitors. Catheter Cardiovasc Interv. 2001;53:346-351.
[61]Bonello L, Camoin-Jau L, Arques S, et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance:A multicenter randomized prospective study. J Am Coll Cardiol.2008;51:1404-1411.
[62]Price MJ, Berger PB, Teirstein PS, et al. Standard-vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention:The gravitas randomized trial. JAMA.2011;305:1097-1105.
[63]Collet JP, Cuisset T, Range G, et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med.2012;367:2100-2109.
[64]Lee SW, Park SW, Kim YH, et al. Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the declare-diabetes trial (a randomized comparison of triple antiplatelet therapy with dual antiplatelet therapy after drug-eluting stent implantation in diabetic patients). J Am Coll Cardiol.2008;51:1181-1187.
[65]Storey RF. The p2yl2 receptor as a therapeutic target in cardiovascular disease. Platelets.2001; 12:197-209.
[66]Leibundgut G, Pache J, Schulz S, et al. Collagen plug vascular closure devices and reduced risk of bleeding with bivalirudin versus heparin plus abciximab in patients undergoing percutaneous coronary intervention for non st-segment elevation myocardial infarction. J Interv Cardiol.2013;26:623-629.
[67]Farid NA, Smith RL, Gillespie TA, et al. The disposition of prasugrel, a novel thienopyridine, in humans. Drug Metab Dispos.2007;35:1096-1104.
[68]Wiviott SD, Trenk D, Frelinger AL, et al. Prasugrel compared with high loading-and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention:The prasugrel in comparison to clopidogrel for inhibition of platelet activation and aggregation-thrombolysis in myocardial infarction 44 trial. Circulation. 2007;116:2923-2932.
[69]Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med.2007;357:2001-2015.
[70]Gurbel PA, Bliden KP, Butler K, et al. Randomized double-blind assessment of the onset and offset of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease:The onset/offset study. Circulation. 2009; 120:2577-2585.
[71]Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med.2009;361:1045-1057.
[2]YusufS, ZhaoF, Mehta SR, et al. Efects of clopidogrel in addition to aspirin in pa tients with acute coronary syndromes without ST-segment elevation. N Engl J Med, 2001,345(7):494-502.
[3]Sebatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and flbrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med,2005,352(12):1179-1189.
[4]Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Variability in individual responsiveness to clopidogrel:Clinical implications, management, and future perspectives. J Am Coll Cardiol.2007;49:1505-1516.
[5]Ong AT, Hoye A, Aoki J, et al. Thirty day incidence and six month clinical outcome of thrombotic stent occlusion after bare metal, sirolimus, or paclitaxel stent implantation. J Am Coll Cardiol,2005,45(6):947-953.
[6]Lakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug eluting stents. JAMA,2005,293(17): 2126-2130.
[7]Kazui M, Nishiya Y, Ishizuka T, et al. Identification of the human cytochrome p450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos.2010;38:92-99.
[8]Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med.2009; 360:363-375.
[9]Mega JL, Close SL, Wiviott SD, et al. Genetic variants in abcbl and cyp2cl9 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the triton-timi 38 trial:A pharmacogenetic analysis. Lancet.2010;376:1312-1319.
[10]Jaitner J, Morath T, Byrne RA, et al. No association of abcbl c3435t genotype with clopidogrel response or risk of stent thrombosis in patients undergoing coronary stenting. Circ Cardiovasc Interv.2012;5:82-88.
[11]Luo M, Li J, Xu X, et al. Abcbl c3435t polymorphism and risk of adverse clinical events in clopidogrel treated patients:A meta-analysis. Thromb Res. 2012;129:754-759.
[12]Rideg O, Komocsi A, Magyarlaki T, et al. Impact of genetic variants on post-clopidogrel platelet reactivity in patients after elective percutaneous coronary intervention. Pharmacogenomics.2011;12:1269-1280.
[13]Staritz P, Kurz K, Stoll M, et al. Platelet reactivity and clopidogrel resistance are associated with the h2 haplotype of the p2yl2-adp receptor gene. Int J Cardiol. 2009;133:341-345.
[14]von Beckerath N, von Beckerath O, Koch W, et al. P2y12 gene h2 haplotype is not associated with increased adenosine diphosphate-induced platelet aggregation after initiation of clopidogrel therapy with a high loading dose. Blood Coagul Fibrinolysis. 2005;16:199-204.
[15]Cuisset T, Frere C, Quilici J, et al. Role of the t744c polymorphism of the p2y12 gene on platelet response to a 600-mg loading dose of clopidogrel in 597 patients with non-st-segment elevation acute coronary syndrome. Thromb Res.2007;120: 893-899.
[16]Mega JL, Simon T, Collet JP, et al. Reduced-function cyp2c19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for pci:A meta-analysis. JAMA.2010;304:1821-1830.
[17]Giusti B, Gori AM, Marcucci R, et al. Relation of cytochrome p450 2c 19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis. Am J Cardiol.2009; 103:806-811.
[18]Sibbing D, Stegherr J, Latz W, et al. Cytochrome p450 2c19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. Eur Heart J.2009;30:916-922.
[19]Man M, Farmen M, Dumaual C, et al. Genetic variation in metabolizing enzyme and transporter genes:Comprehensive assessment in 3 major east asian subpopulations with comparison to caucasians and africans. J Clin Pharmacol.2010;50:929-940.
[20]Guidelines for percutaneous transluminal coronary angioplasty. A report of the American College of Cardiology/American Heart Association Task Force on assessment of diagnostic and therapeuitic cardiovascular procedures (subcommittee on percutaneous transluminal coronary argioplasty). Circulation,1988,78(2): 486-502.
[21]Levine GN, Bates ER, Blankenship JC, et al.2011 accf/aha/scai guideline for percutaneous coronary intervention:A report of the american college of cardiology foundation/american heart association task force on practice guidelines and the society for cardiovascular angiography and interventions. Catheter Cardiovasc Interv. 2013;82:E266-355.
[22]Levine GN, Bates ER, Blankenship JC, et al.2011 accf/aha/scai guideline for percutaneous coronary intervention:A report of the american college of cardiology foundation/american heart association task force on practice guidelines and the society for cardiovascular angiography and interventions. Circulation. 2011;124:e574-651.
[23]Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: A case for standardized definitions. Circulation.2007;115:2344-2351.
[24]Whitworth JA,2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens.2003, 21(11):1983-1992.
[25]Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1:diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med,1998,15(7):539-553.
[26]Kato N, Sugiyama T, Morita H, et al. Genetic analysis of the atrial natriuretic peptide gene in essential hypertension. Clin Sci (Lond).2000;98:251-258.
[27]Steinhubl SR, Berger PB, Mann JT, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention:a randomized controlled trial. JAMA,2002,288(19):2411-2420.
[28]Gerschutz GP, Bhatt DL, et al. The Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) study:to what extent should the results be generalizable? Am Heart J,2003,145(4):595-601.
[29]Taubert D, von Beckerath N, Grimberg G, et al. Impact of p-glycoprotein on clopidogrel absorption. Clin Pharmacol Ther.2006;80:486-501.
[30]Lee JM, Park S, Shin DJ, et al. Relation of genetic polymorphisms in the cytochrome p450 gene with clopidogrel resistance after drug-eluting stent implantation in koreans. Am J Cardiol.2009; 104:46-51.
[31]Goldstein JA, Ishizaki T, Chiba K, et al. Frequencies of the defective cyp2c19 alleles responsible for the mephenytoin poor metabolizer phenotype in various oriental, caucasian, saudi arabian and american black populations. Pharmacogenetics. 1997;7:59-64.
[32]Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Contribution of gene sequence variations of the hepatic cytochrome p450 3a4 enzyme to variability in individual responsiveness to clopidogrel. Arterioscler Thromb Vasc Biol.2006;26:1895-1900.
[33]Kreutz RP, Owens J, Jin Y, et al. Cytochrome p450 3a4*22, ppar-alpha, and arnt polymorphisms and clopidogrel response. Clin Pharmacol.2013;5:185-192.
[34]Suh JW, Koo BK, Zhang SY, et al. Increased risk of atherothrombotic events associated with cytochrome p450 3a5 polymorphism in patients taking clopidogrel. CMAJ.2006; 174:1715-1722.
[35]Park KW, Kang J, Park JJ, et al. Amlodipine, clopidogrel and cyp3a5 genetic variability:Effects on platelet reactivity and clinical outcomes after percutaneous coronary intervention. Heart.2012;98:1366-1372.
[36]Fontana P, Gaussem P, Aiach M, et al. P2y12 h2 haplotype is associated with peripheral arterial disease:A case-control study. Circulation.2003; 108:2971-2973.
[37]Ziegler S, Schillinger M, Funk M, et al. Association of a functional polymorphism in the clopidogrel target receptor gene, p2y12, and the risk for ischemic cerebrovascular events in patients with peripheral artery disease. Stroke. 2005;36:1394-1399.
[38]Preobrazhenskii DV, Sidorenko BA, Batyraliev TA, et al. Thienopyridines in the treatment and prevention of cardiovascular diseases. Part ii. Clinical pharmacology of clopidogrel. Kardiologiia.2009;49:88-96.
[39]Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Lack of association between the p2y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease. Thromb Res.2005;116:491-497.
[1]Gurbel PA, Bliden KP, Hayes KM, et al. Platelet activation in myocardial ischemic syndromes. Expert Rev Cardiovasc Ther.2004;2:535-545.
[2]Gurbel PA, Bliden KP, Samara W, et al. Clopidogrel effect on platelet reactivity in patients with stent thrombosis:Results of the crest study. J Am Coll Cardiol. 2005;46:1827-1832.
[3]Levine GN, Bates ER, Blankenship JC, et al.2011 accf/aha/scai guideline for percutaneous coronary intervention:A report of the american college of cardiology foundation/american heart association task force on practice guidelines and the society for cardiovascular angiography and interventions. Catheter Cardiovasc Interv. 2013;82:E266-355.
[4]Anderson JL, Adams CD, Antman EM, et al.2011 accf/aha focused update incorporated into the acc/aha 2007 guidelines for the management of patients with unstable angina/non-st-elevation myocardial infarction:A report of the american college of cardiology foundation/american heart association task force on practice guidelines. Circulation.2011;123:e426-579.
[5]Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation.2004;109:3171-3175.
[6]Price MJ, Endemann S, Gollapudi RR, et al. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J.2008;29:992-1000.
[7]Bonello L, Camoin-Jau L, Arques S, et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance:A multicenter randomized prospective study. J Am Coll Cardiol.2008;51:1404-1411.
[8]Bliden KP, DiChiara J, Tantry US, et al. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention:Is the current antiplatelet therapy adequate? J Am Coll Cardiol. 2007;49:657-666.
[9]Angiolillo DJ, Capranzano P, Desai B, et al. Impact of p2y(12) inhibitory effects induced by clopidogrel on platelet procoagulant activity in type 2 diabetes mellitus patients. Thromb Res.2009;124:318-322.
[10]Gurbel PA, Bliden KP, Guyer K, et al. Platelet reactivity in patients and recurrent events post-stenting:Results of the prepare post-stenting study. J Am Coll Cardiol, 2005;46:1820-1826.
[11]Kim IS, Jeong YH, Kang MK, et al. Correlation of high post-treatment platelet reactivity assessed by light transmittance aggregometry and the verifynow p2y12 assay. J Thromb Thrombolysis.2010;30:486-495.
[12]Kim IS, Jeong YH, Tantry US, et al. Relation between the vasodilator-stimulated phosphoprotein phosphorylation assay and light transmittance aggregometry in east asian patients after high-dose clopidogrel loading. Am Heart J.2013;166:95-103.
[13]Guidelines for percutaneous transluminal coronary angioplasty. A report of the American College of Cardiology/American Heart Association Task Force on assessment of diagnostic and therapeuitic cardiovascular procedures (subcommittee on percutaneous transluminal coronary argioplasty). Circulation,1988,78(2): 486-502.
[14]Levine GN, Bates ER, Blankenship JC, et al.2011 accf/aha/scai guideline for percutaneous coronary intervention:A report of the american college of cardiology foundation/american heart association task force on practice guidelines and the society for cardiovascular angiography and interventions. Circulation. 2011;124:e574-651.
[15]Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: A case for standardized definitions. Circulation.2007; 115:2344-2351.
[16]Whitworth JA,2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens.2003, 21(11):1983-1992.
[17]Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1:diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med,1998,15(7):539-553.
[18]Kato N, Sugiyama T, Morita H, et al. Genetic analysis of the atrial natriuretic peptide gene in essential hypertension. Clin Sci (Lond).2000;98:251-258.
[19]Gabriel SA, Beteli CB, Tanighuchi RS, et al. Aspirin resistance and atherothrombosis. Rev Bras Cir Cardiovasc.2007;22:96-103.
[20]Hochholzer W, Trenk D, Bestehorn HP, et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol.2006;48:1742- 1750.
[21]Gurbel PA, Bliden KP, Samara W, et al. Clopidogrel effect on platelet reactivity in patients with stent thrombosis:Results of the crest study. J Am Coll Cardiol. 2005;46:1827-1832.
[22]Breet NJ, van Werkum JW, Bouman HJ, et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA.2010;303:754-762.
[23]Tantry US, Bonello L, Aradi D, et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol.2013;62:2261-2273.
[24]Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Variability in individual responsiveness to clopidogrel:Clinical implications, management, and future perspectives. J Am Coll Cardiol.2007;49:1505-1516.
[25]Stein B, Weintraub WS, Gebhart SP, et al. Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty. Circulation. 1995;91:979-989.
[26]Song YB, Hahn JY, Gwon HC, et al. A high loading dose of clopidogrel reduces myocardial infarct size in patients undergoing primary percutaneous coronary intervention:A magnetic resonance imaging study. Am Heart J.2012;163:500-507.
[27]Tantry US, Bliden KP, Suarez TA, et al. Hypercoagulability, platelet function, inflammation and coronary artery disease acuity:Results of the thrombotic risk progression (trip) study. Platelets.2010;21:360-367.
[28]Park KW, Kang SH, Park JJ, et al. Adjunctive cilostazol versus double-dose clopidogrel after drug-eluting stent implantation:The host-assure randomized trial (harmonizing optimal strategy for treatment of coronary artery stenosis-safety & effectiveness of drug-eluting stents & anti-platelet regimen). JACC Cardiovasc Interv. 2013;6:932-942.
[29]Park DW, Yun SC, Lee JY, et al. C-reactive protein and the risk of stent thrombosis and cardiovascular events after drug-eluting stent implantation. Circulation. 2009;120:1987-1995.
[30]Albert MA, Glynn RJ, Buring J, et al. C-reactive protein levels among women of various ethnic groups living in the united states (from the women's health study). Am J Cardiol.2004;93:1238-1242.
[31]Gurbel PA, Bliden KP, Navickas IA, et al. Adenosine diphosphate-induced platelet-fibrin clot strength:A new thrombelastographic indicator of long-term poststenting ischemic events. Am Heart J.2010;160:346-354.
[1]YusufS, Zhao F, Mehta SR, et al. Efects of clopidogrel in addition to aspirin in pa tients with acute coronary syndromes without ST-segment elevation. N Engl J Med, 2001,345(7):494-502.
[2]Sebatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and flbrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med,2005,352(12):1179-1189.
[3]Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Variability in individual responsiveness to clopidogrel:Clinical implications, management, and future perspectives. J Am Coll Cardiol.2007;49:1505-1516.
[4]Ong AT, Hoye A, Aoki J, et al. Thirty day incidence and six month clinical outcome of thrombotic stent occlusion after bare metal, sirolimus, or paclitaxel stent implantation. J Am Coll Cardiol,2005,45(6):947-953.
[5]Lakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug eluting stents. JAMA,2005,293(17): 2126-2130.
[6]Man M, Farmen M, Dumaual C, et al. Genetic variation in metabolizing enzyme and transporter genes:Comprehensive assessment in 3 major east asian subpopulations with comparison to Caucasians and africans. J Clin Pharmacol.2010;50:929-940.
[7]Goldstein JA, Ishizaki T, Chiba K, et al. Frequencies of the defective cyp2c19 alleles responsible for the mephenytoin poor metabolizer phenotype in various oriental, Caucasian, saudi arabian and american black populations. Pharmacogenetics. 1997;7:59-64.
[8]Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med.2009; 360:363-375.
[9]Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med.2009;360:354-362.
[10]Tang XF, Wang J, Zhang JH, et al. Effect of the cyp2c192 and 3 genotypes, abcbl c3435t and ponl q192r alleles on the pharmacodynamics and adverse clinical events of clopidogrel in Chinese people after percutaneous coronary intervention. Eur J Clin Pharmacol.2013;69:1103-1112.
[11]Price MJ, Endemann S, Gollapudi RR, et al. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J.2008;29:992-1000.
[12]Brar SS, ten Berg J, Marcucci R, et al. Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data. J Am Coll Cardiol,2011;58::1945-54.
[13]Hamm CW, Bassand JP, Agewall S, et al. Esc guidelines for the management of acute coronary syndromes in patients presenting without persistent st-segment elevation:The task force for the management of acute coronary syndromes (acs) in patients presenting without persistent st-segment elevation of the european society of cardiology (esc). Eur Heart J.2011;32:2999-3054.
[14]Levine GN, Bates ER, Blankenship JC, et al.2011 accf/aha/scai guideline for percutaneous coronary intervention:A report of the american college of cardiology foundation/american heart association task force on practice guidelines and the society for cardiovascular angiography and interventions. Catheter Cardiovasc Interv. 2013;82:E266-355.
[15]O'Gara PT, Kushner FG, Ascheim DD, et al.2013 accf/aha guideline for the management of st-elevation myocardial infarction:A report of the american college of cardiology foundation/american heart association task force on practice guidelines. Circulation.2013;127:e362-425.
[16]Guidelines for percutaneous transluminal coronary angioplasty. A report of the American College of Cardiology/American Heart Association Task Force on assessment of diagnostic and therapeuitic cardiovascular procedures (subcommittee on percutaneous transluminal coronary argioplasty). Circulation,1988,78(2): 486-502.
[17]Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: A case for standardized definitions. Circulation.2007; 115:2344-2351.
[18]Whitworth JA,2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens.2003, 21(11):1983-1992.
[19]Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1:diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med,1998,15(7):539-553.
[20]中国成人血脂异常防治指南制订联合委员会。中国成人血脂异常防治指南。中华心血管病杂志,2007,35(5)：390-413.
[21]叶任高,陆再英。内科学[M]。第6版,北京：人民卫生出版社,2005：558.
[22]Wang TY,Ou FS,Roe MT,et al.Incidence and prognostic significance ofthrombocytopenia developed during acute coronary syndrome in contemporaryclinical practice.Circulation.2009;119：2454-2462.
[23]Kato N,Sugiyama T,Morita H,et al.Genetic analysis of the atrial natriureticpeptide gene in essential hypertension.Clin Sci(Lond).2000；98：251-258.
[24]Bliden KP,DiChiara J,Tantry US,et al.Increased risk in patients with high plateletaggregation receiving chronic clopidogrel therapy undergoing percutaneous coronaryintervention：Is the current antiplatelet therapy adequate? J Am Coll Cardiol.2007;49：657-666.
[25]Pencina MJ,D'Agostino RB,Sr.,D'Agostino RB,et al.Evaluating the addedpredictive ability of a new marker：From area under the roc curve to reclassificationand beyond.Stat Med.2008；27：157-172；discussion 207-112.
[26]Kazui M,Nishiya Y,Ishizuka T,et al.Identification of the human cytochrome p450enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to itspharmacologically active metabolite.Drug Metab Dispos.2010；38：92-99.
[27]Shuldiner AR,O'Connell JR,Bliden KP,et al.Association of cytochrome p4502c19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.JAMA.2009;302：849-857.
[28]Scott SA,Sangkuhl K,Gardner EE,et al.Clinical pharmacogenetics implementationconsortium guidelines for cytochrome p450-2c19(cyp2c19)genotype andclopidogrel therapy.Clin Pharmacol Ther.2011；90：328-332.
[29]Mega JL,Simon T,Collet JP,et al.Reduced-function cyp2c19 genotype and risk ofadverse clinical outcomes among patients treated with clopidogrel predominantly forpci：A meta-analysis.JAMA.2010；304：1821-1830.
[30]Gurbel PA,Bliden KP,Navickas IA,et al.Adenosine diphosphate-inducedplatelet-fibrin clot strength：A new thrombelastographic indicator of long-termpoststenting ischemic events.Am Heart J.2010；160：346-354.
[31]Stone G W,Witzenbichler B,Weisz G,et al.Platelet reactivity and clinical outcomesafter coronary artery implantation of drug-eluting stents(adapt-des)：A prospectivemulticentre registry study.Lancet.2013；382：614-623.
[32]Breet NJ,van Werkum JW,Bouman HJ,et al.Comparison of platelet function testsin predicting clinical outcome in patients undergoing coronary stent implantation.JAMA.2010;303：754-762.
[33]Miller M,Kwiterovich PO,Jr.Isolated low hdl-cholesterol as an important risk factor for coronary heart disease. Eur Heart J.1990;11 Suppl H:9-14.
[34]Gotto AM, Jr., Brinton EA. Assessing low levels of high-density lipoprotein cholesterol as a risk factor in coronary heart disease:A working group report and update. JAm Coll Cardiol.2004;43:717-724.
[35]Lee PC, Kini AS, Ahsan C, et al. Anemia is an independent predictor of mortality after percutaneous coronary intervention. J Am Coll Cardiol.2004;44:541-546.
[36]Campo G, Parrinello G, Ferraresi P, et al. Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome. J Am Coll Cardiol.2011;57:2474-2483.
[37]Price MJ, Berger PB, Teirstein PS, et al. Standard-vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention:The gravitas randomized trial. JAMA.2011;305:1097-1105.
[1]Xiang YZ, Xia Y, Gao XM, et al. Platelet activation, and antiplatelet targets and agents:Current and novel strategies. Drugs.2008;68:1647-1664.
[2]Jennings LK, Saucedo JF. Antiplatelet and anticoagulant agents:Key differences in mechanisms of action, clinical application, and therapeutic benefit in patients with non-st-segment-elevation acute coronary syndromes. Curr Opin Cardiol. 2008;23:302-308.
[3]Levine GN, Bates ER, Blankenship JC, et al.2011 accf/aha/scai guideline for percutaneous coronary intervention:A report of the american college of cardiology foundation/american heart association task force on practice guidelines and the society for cardiovascular angiography and interventions. Catheter Cardiovasc Interv. 2013;82:E266-355.
[4]Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with st-segment elevation. N Engl J Med.2005;352:1179-1189.
[5]Serebruany VL, Steinhubl SR, Berger PB, et al. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol.2005;45:246-251.
[6]Gurbel PA, Bliden KP, Hiatt BL, et al. Clopidogrel for coronary stenting:response variability drug resistance and the effect of pretreatment platelet reactivity. Circulation,2003,107(23):2908-2913.
[7]Muller I, Besta F, Schulz C, et al. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost.2003;89:783-787.
[8]Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation.2004;109:3171-3175.
[9]Kazui M, Nishiya Y, Ishizuka T, et al. Identification of the human cytochrome p450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos.2010;38:92-99.
[10]Ding Z, Kim S, Dorsam RT, et al. Inactivation of the human p2y12 receptor by thiol reagents requires interaction with both extracellular cysteine residues, cys17 and cys270. Blood.2003;101:3908-391.
[11]Patrono C, Bachmann F, Baigent C, et al. [expert consensus document on the use of antiplatelet agents]. Rev Esp Cardiol.2004;57:963-980.
[12]Mehta SR, Yusuf S. The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme; rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease. Eur Heart J,2000,21(24):2033-41.
[13]Mehta S, Yusuf S, Peters R, P et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undrgoing percutaneous coronary intervention:The PCI-CURE study. Lancet,2001,358(9281):527-533.
[14]Chen ZM, Jiang LX, Chen YP, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction:randomised placebo-controlled trial. Lancet, 2005,366 (9497):1607-1621.
[15]Steinhubl SR, Berger PB, Mann JT, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention:a randomized controlled trial. JAMA,2002,288(19):2411-20.
[16]Barragan P, Bouvier JL, Roquebert PO, et al. Resistance to thienopyridines:clinieal detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phos-phorylation. Catheter Cardiovasc Interv,2003,59(3):295-302.
[17]Bliden KP, DiChiara J, Tantry US, et al. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention:Is the current antiplatelet therapy adequate? J Am Coll Cardiol. 2007;49:657-666.
[18]Breet NJ, van Werkum JW, Bouman HJ, et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA.2010;303:754-762.
[19]Bonello L, Tantry US, Marcucci R, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol.2010;56:919-933.
[20]Tantry US, Bonello L, Aradi D, et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol.2013;62:2261-2273.
[21]Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Variability in individual responsiveness to clopidogrel:Clinical implications, management, and future perspectives. J Am Coll Cardiol.2007;49:1505-1516.
[22]Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med.2009; 360:363-375.
[23]Mega JL, Close SL, Wiviott SD, et al. Genetic variants in abcbl and cyp2c19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the triton-timi 38 trial:A pharmacogenetic analysis. Lancet.2010;376:1312-1319.
[24]Jaitner J, Morath T, Byrne RA, et al. No association of abcbl c3435t genotype with clopidogrel response or risk of stent thrombosis in patients undergoing coronary stenting. Circ Cardiovasc Interv:2012;5:82-88.
[25]Tang XF, Wang J, Zhang JH, et al. Effect of the cyp2c192 and 3 genotypes, abcbl c3435t and ponl q192r alleles on the pharmacodynamics and adverse clinical events of clopidogrel in Chinese people after percutaneous coronary intervention. Eur J Clin Pharmacol.2013;69:1103-1112.
[26]Sim SC, Miller WL, Zhong XB, et al. Nomenclature for alleles of the cytochrome p450 oxidoreductase gene. Pharmacogenet Genomics.2009;19:565-566.
[27]Liang ZY, Han YL, Zhang XL, et al. The impact of gene polymorphism and high on-treatment platelet reactivity on clinical follow-up:Outcomes in patients with acute coronary syndrome after drug-eluting stent implantation. EuroIntervention. 2013;9:316-327.
[28]Mega JL, Simon T, Collet JP, et al. Reduced-function cyp2c19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for pci:A meta-analysis. JAMA.2010;304:1821-1830.
[29]Giusti B, Gori AM, Marcucci R, et al. Relation of cytochrome p450 2c19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis. Am J Cardiol.2009;103:806-811.
[30]Sibbing D, Stegherr J, Latz W, et al. Cytochrome p450 2c19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. Eur Heart J.2009;30:916-922.
[31]Eiselt R, Domanski TL, Zibat A, et al. Identification and functional characterization of eight cyp3a4 protein variants. Pharmacogenetics.2001;11:447-458.
[32]Liu YT, Hao HP, Liu CX, et al. Drugs as cyp3a probes, inducers, and inhibitors. Drug Metab Rev.2007;39:699-721.
[33]Lakhman SS, Ma Q, Morse GD. Pharmacogenomics of cyp3a:Considerations for hiv treatment. Pharmacogenomics.2009;10:1323-1339.
[34]Lau WC, Gurbel PA, Watkins PB, et al. Contribution of hepatic cytochrome p450 3a4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation. 2004;109:166-171.
[35]Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Contribution of gene sequence variations of the hepatic cytochrome p450 3a4 enzyme to variability in individual responsiveness to clopidogrel. Arterioscler Thromb Vase Biol.2006;26:1895-1900.
[36]Giusti B, Gori AM, Marcucci R, et al. Cytochrome p450 2c19 loss-of-function polymorphism, but not cyp3a4 ivs10+12g/a and p2y12 t744c polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients. Pharmacogenet Genomics.2007;17:1057-1064.
[37]Kreutz RP, Owens J, Jin Y, et al. Cytochrome p450 3a4*22, ppar-alpha, and arnt polymorphisms and clopidogrel response. Clin Pharmacol.2013;5:185-192.
[38]Suh JW, Koo BK, Zhang SY, et al. Increased risk of atherothrombotic events associated with cytochrome p450 3a5 polymorphism in patients taking clopidogrel. CMAJ.2006;174:1715-1722.
[39]Kim KA, Park PW, Park JY. Effect of cyp3a5*3 genotype on the pharmacokinetics and antiplatelet effect of clopidogrel in healthy subjects. Eur J Clin Pharmacol. 2008;64:589-597.
[40]Park KW, Kang J, Park JJ, et al. Amlodipine, clopidogrel and cyp3a5 genetic variability:Effects on platelet reactivity and clinical outcomes after percutaneous coronary intervention. Heart.2012;98:1366-1372.
[41]Fontana P, Gaussem P, Aiach M, et al. P2y12 h2 haplotype is associated with peripheral arterial disease:A case-control study. Circulation.2003;108:2971-2973.
[42]Staritz P, Kurz K, Stoll M, et al. Platelet reactivity and clopidogrel resistance are associated with the h2 haplotype of the p2yl2-adp receptor gene, Int J Cardiol. 2009;133:341-345.
[43]von Beckerath N, von Beckerath O, Koch W, et al. P2y12 gene h2 haplotype is not associated with increased adenosine diphosphate-induced platelet aggregation after initiation of clopidogrel therapy with a high loading dose. Blood Coagul Fibrinolysis. 2005;16:199-204.
[44]Cuisset T, Frere C, Quilici J, et al. Role of the t744c polymorphism of the p2y12 gene on platelet response to a 600-mg loading dose of clopidogrel in 597 patients with non-st-segment elevation acute coronary syndrome. Thromb Res.2007; 120: 893-899.
[45]Malek LA, Kisiel B, Spiewak M, et al. Coexisting polymorphisms of p2y12 and cyp2c19 genes as a risk factor for persistent platelet activation with clopidogrel. Circ J.2008;72:1165-1169.
[46]Tang XF, Zhang JH, Wang J, et al. Effects of coexisting polymorphisms of cyp2cl9 and p2yl2 on clopidogrel responsiveness and clinical outcome in patients with acute coronary syndromes undergoing stent-based coronary intervention. Chin Med J (Engl).2013;126:1069-1075.
[47]Giusti B, Gori AM, Marcucci R, et al. Role of glycoprotein ia gene polymorphisms in determining platelet function in myocardial infarction patients undergoing percutaneous coronary intervention on dual antiplatelet treatment. Atherosclerosis. 2008;196:341-348.
[48]Feher G, Koltai K, Alkonyi B, Papp E, Keszthelyi Z, Kesmarky G, Toth K. Clopidogrel resistance:Role of body mass and concomitant medications. Int J Cardiol 2007;120:188-192.
[49]Lev El, Patel RT, Maresh KJ, et al. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention:The role of dual drug resistance. J Am Coll Cardiol.2006;47:27-33.
[50]Frere C, Cuisset T, Quilici J, et al. Adp-induced platelet aggregation and platelet reactivity index vasp are good predictive markers for clinical outcomes in non-st elevation acute coronary syndrome. Thromb Haemost.2007;98:838-843.
[51]Jin HY, Yang TH, Kim DI, et al. High post-clopidogrel platelet reactivity assessed by a point-of-care assay predicts long-term clinical outcomes in patients with st-segment elevation myocardial infarction who underwent primary coronary stenting. Int J Cardiol.2013;167:1877-1881.
[52]Ades PA, Savage PD, Toth MJ, et al. The influence of obesity and consequent insulin resistance on coronary risk factors in medically treated patients with coronary disease. Int JObes (Lond).2008;32:967-974.
[53]Lepantalo A, Virtanen KS, Heikkila J, et al. Limited early antiplatelet effect of 300 mg clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions. Eur Heart J.2004;25:476-483.
[54]Gabriel SA, Beteli CB, Tanighuchi RS, et al. Aspirin resistance and atherothrombosis. Rev Bras Cir Cardiovasc.2007;22:96-103.
[55]Zhou L, Schmaier AH. Platelet aggregation testing in platelet-rich plasma: Description of procedures with the aim to develop standards in the field. Am J Clin Pathol.2005;123:172-183.
[56]Hobson AR, Petley GW, Dawkins KD, et al. A novel fifteen minute test for assessment of individual time-dependent clotting responses to aspirin and clopidogrel using modified thrombelastography. Platelets.2007;18:497-505.
[57]Malinin A, Pokov A, Spergling M, et al. Monitoring platelet inhibition after clopidogrel with the verifynow-p2yl2(r) rapid analyzer:The verify thrombosis risk assessment (veritas) study. Thromb Res.2007; 119:277-284.
[58]Jakubowski JA, Li YG, Small DS, et al. A comparison of the verifynow p2y12 point-of-care device and light transmission aggregometry to monitor platelet function with prasugrel and clopidogrel:An integrated analysis. J Cardiovasc Pharmacol. 2010;56:29-37.
[59]Jilma B. Platelet function analyzer (pfa-100):A tool to quantify congenital or acquired platelet dysfunction. J Lab Clin Med.2001; 138:152-163.
[60]Lakkis NM, George S, Thomas E, et al. Use of ichor-platelet works to assess platelet function in patients treated with gp iib/iiia inhibitors. Catheter Cardiovasc Interv. 2001;53:346-351.
[61]Bonello L, Camoin-Jau L, Arques S, et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance:A multicenter randomized prospective study. J Am Coll Cardiol.2008;51:1404-1411.
[62]Price MJ, Berger PB, Teirstein PS, et al. Standard-vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention:The gravitas randomized trial. JAMA.2011;305:1097-1105.
[63]Collet JP, Cuisset T, Range G, et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med.2012;367:2100-2109.
[64]Lee SW, Park SW, Kim YH, et al. Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the declare-diabetes trial (a randomized comparison of triple antiplatelet therapy with dual antiplatelet therapy after drug-eluting stent implantation in diabetic patients). J Am Coll Cardiol.2008;51:1181-1187.
[65]Storey RF. The p2yl2 receptor as a therapeutic target in cardiovascular disease. Platelets.2001; 12:197-209.
[66]Leibundgut G, Pache J, Schulz S, et al. Collagen plug vascular closure devices and reduced risk of bleeding with bivalirudin versus heparin plus abciximab in patients undergoing percutaneous coronary intervention for non st-segment elevation myocardial infarction. J Interv Cardiol.2013;26:623-629.
[67]Farid NA, Smith RL, Gillespie TA, et al. The disposition of prasugrel, a novel thienopyridine, in humans. Drug Metab Dispos.2007;35:1096-1104.
[68]Wiviott SD, Trenk D, Frelinger AL, et al. Prasugrel compared with high loading-and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention:The prasugrel in comparison to clopidogrel for inhibition of platelet activation and aggregation-thrombolysis in myocardial infarction 44 trial. Circulation. 2007;116:2923-2932.
[69]Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med.2007;357:2001-2015.
[70]Gurbel PA, Bliden KP, Butler K, et al. Randomized double-blind assessment of the onset and offset of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease:The onset/offset study. Circulation. 2009; 120:2577-2585.
[71]Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med.2009;361:1045-1057.